Limited utility of qPCR-based detection of tumor-specific circulating mRNAs in whole blood from clear cell renal cell carcinoma patients by Simonovic, S. et al.
RESEARCH ARTICLE Open Access
Limited utility of qPCR-based detection of
tumor-specific circulating mRNAs in whole
blood from clear cell renal cell carcinoma
patients
Sinisa Simonovic1,2,3* , Christian Hinze3, Kai M. Schmidt-Ott3,4, Jonas Busch1, Monika Jung1, Klaus Jung1,2 and
Anja Rabien1,2
Abstract
Background: RNA sequencing data is providing abundant information about the levels of dysregulation of genes
in various tumors. These data, as well as data based on older microarray technologies have enabled the identification
of many genes which are upregulated in clear cell renal cell carcinoma (ccRCC) compared to matched normal tissue.
Here we use RNA sequencing data in order to construct a panel of highly overexpressed genes in ccRCC so as to
evaluate their RNA levels in whole blood and determine any diagnostic potential of these levels for renal cell
carcinoma patients.
Methods: A bioinformatics analysis with Python was performed using TCGA, GEO and other databases to identify
genes which are upregulated in ccRCC while being absent in the blood of healthy individuals. Quantitative Real Time
PCR (RT-qPCR) was subsequently used to measure the levels of candidate genes in whole blood (PAX gene) of 16
ccRCC patients versus 11 healthy individuals. PCR results were processed in qBase and GraphPadPrism and statistics
was done with Mann-Whitney U test.
Results: While most analyzed genes were either undetectable or did not show any dysregulated expression, two
genes, CDK18 and CCND1, were paradoxically downregulated in the blood of ccRCC patients compared to healthy
controls. Furthermore, LOX showed a tendency towards upregulation in metastatic ccRCC samples compared to non-
metastatic.
Conclusions: This analysis illustrates the difficulty of detecting tumor regulated genes in blood and the possible
influence of interference from expression in blood cells even for genes conditionally absent in normal blood. Testing in
plasma samples indicated that tumor specific mRNAs were not detectable. While CDK18, CCND1 and LOX mRNAs
might carry biomarker potential, this would require validation in an independent, larger patient cohort.
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Background
In the United States, it is estimated that 65,340 new cases
and 14,970 deaths from kidney cancer will occur in 2018
[1]. ccRCC is the most common renal malignancy, ac-
counting for around 80% of the cases [2]. Together with
papillary and chromophobe carcinoma, it comprises 2% of
all cancers worldwide [3]. Renal cell carcinoma (RCC) in-
cidence increases markedly with age, peaking at 50–70
years, with males being affected twice more frequently
than females [4]. The major risk factors for RCC include
excess body weight, hypertension and cigarette smoking
[5] and associations have also been made with different
lifestyle, dietary, occupational and environmental factors
[6]. Primary RCC displays no early clinical symptoms as
most renal masses remain asymptomatic until the late
stages of the disease, with over 50% of all cases of RCC
being discovered by chance during imaging studies for
other comorbidities [7, 8]. Only 10% of patients have the
classical triad of symptoms: hematuria, flank pain and
weight loss. Around 25% of RCCs have already metasta-
sized by the time of diagnosis [9]. RCC is mostly unre-
sponsive to conventional chemotherapy and radiation,
which is the main reason for treatment failures [10, 11].
The gold standard for the management of renal masses is
nephrectomy, in spite of which approximately 30% of
patients develop recurrence or metastases [12, 13], which
require systemic therapies and are associated with high
mortality.
As current prognostic models based on conventional
clinicopathological and imaging data have limited accur-
acy, new biomarkers are needed for early detection, im-
proved diagnostics and the prediction of the clinical
outcome of patients with RCC [14–17]. The ideal bio-
marker or biomarker panel should have high specificity,
sensitivity, and reproducibility. Plasma, serum, and urine
have recently gained interest in the field of cancer bio-
marker discovery. They represent potential sources of
valuable biomarkers, containing proteins, DNA, and
various RNA species, with blood being especially suitable
in terms of kidney disease and low invasiveness. Steady
progress in the field is being made, however to date,
none of the identified ccRCC biomarkers have been clin-
ically validated [18].
RNA circulating in blood is highly degraded (usually
less than 100 bp in length [19]) and even after the intro-
duction of systems that enable the stabilization and stor-
age of whole blood mRNA (e.g. the PAXgene platform)
studies tend to be limited to shorter RNA subspecies, or
those protected from degradation due to their specific
structure or association with proteins or membranous
vesicular structures such as exosomes. Analyzing ccRCC
biomarkers in urine would be particularly convenient,
however this field is far less fruitful compared to blood
studies. Similarly as for blood, urine is problematic in
terms of RNA detection because of the presence of RN-
Ases, but also because of PCR inhibition [20], which is
steering the focus into the analysis of shorter RNA sub-
species. Especially in the case of microRNA (miRNA), li-
quid biopsy has expanded from use in plasma to other
bodily fluids in an increasing number of malignancies,
making rapid progress since 2008 [21]. Along with
miRNA, the use of Circulating Tumor Cells (CTCs), cell
free DNA (cfDNA), and more recently circular RNA
(circRNA) and long non-coding RNAs (lncRNA), are
proving to be far more viable strategies, as for most tu-
mors there is somewhat sporadic progress in detecting
tumor-derived mRNA in blood and associating it with
cancer prognosis, for example as described here [22–24].
A further issue that complicates tumor-derived RNA de-
tection in blood is the uncertainty regarding the exact
RNA origin, i.e. whether it is derived from solid tumor
or CTCs, and what percentage of source cells are living
and actively secreting RNA as opposed to undergoing
apoptosis [25].
The first of the five proposed stages in biomarker de-
velopment is the comparison of tumor with nontumor
tissue [26]. Here techniques such as microarrays and
more recently RNAseq are used to assess gene expres-
sion, while protein expression profiles are based on
immunohistochemistry and mass spectroscopy, with the
goal of discovering genes displaying dysregulation (usu-
ally overexpression in tumor compared to normal tis-
sue). This phase is followed by the development of a
clinical assay utilizing blood for non-invasive screening.
Of course, the blood levels of selected genes do not have
to precicely mirror the expression in tissue, as a result of
e.g. the specific rate of mRNA release from cancer tissue
into blood. The approach of using mRNA expression of
tumor tissue as a starting point and analyzing the levels
od respective transcripts in blood by RT-qPCR has been
previously used with success, resulting in promising
assays deserving of clinical validation. A recent study
showed the validation of an RT-PCR assay based on
prostate-specific RNA in whole blood from patients with
metastatic castration-resistant prostate cancer (mCRPC)
[27]. Several databases were consulted to select a panel
of genes that were overexpressed in prostate tissue but
showed no detection in peripheral blood mononuclear
cells (PBMC). This was followed by RT-PCR analysis of
blood samples of cancer patients and volunteers, result-
ing in the establishment of a 5-gene panel that enhances
and complements the previously established CTC enu-
meraration assay. Similarly, in another study focusing on
early detection of colorectal cancer [28], meta-analysis of
microarray data was used to identify RNAs with highest
diffeential expression between cancer tissue and normal
blood samples. Subsequent RT-qPCR analysis revealed
that blood expression of 3 specific genes shows
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promising sensitivity and specificity with respect to de-
tection of this cancer.
In this study, TCGA database was used as a starting
point to identify genes which are most highly overex-
pressed in the tissue of ccRCC patients, after which a
subset containing genes that according to other data-
bases have no blood expression was evaluated by qPCR
in whole blood samples from ccRCC patients and
healthy individuals. While RNA transcripts of some of
these genes had good detectability in blood, none of the
genes were significantly up-regulated in blood from
ccRCC patients and two genes paradoxically displayed
downregulation.
Methods
Patients and samples
The staging and grading of the tumor samples were
done according to the 2002 TNM classification and the
Fuhrman grading system [29, 30]. The ccRCC tissue
samples were obtained during partial or radical nephrec-
tomy at the University Hospital Charité in Berlin in
2011 and blood samples in the period between 2010 and
2016. Tissue samples were frozen in liquid nitrogen dir-
ectly after surgical resection and stored at − 80 °C until
RNA extraction. They came from tumor and matched
normal tissue of 3 male patients without diagnosed me-
tastasis (ages: 47–71; tumor stages: 2 x pT1, and pT3;
grading: G1, G2, G3). PAXgene blood samples were ob-
tained from 27 individuals and included 16 ccRCC sam-
ples, out of which 10 were non-metastatic (8 male and 2
female patients; median age 70, range 47–84 years;
tumor staging: 1x pT1, 2x pT2, 7x pT3; grading: 2x G1,
7x G2, 1x G3) and 6 metastatic: (5 male and 1 female
patients; median age 67, range 47–72 years; tumor sta-
ging: 6x pT3; grading: 5x G2, 1x G3). In total there were
11 samples without diagnosed cancer, 4 from patients
suffering from non-cancer kidney illnesses, and 7 healthy
volunteers (7 male and 4 female; median age 47, range
29–80 years).
Bioinformatics analysis
The first stage in gene selection was the analysis of
ccRCC expression in TCGA database, followed by the
use of GEO and GTEx databases to remove genes
present in blood (Fig. 1). Subsequently, in order to
evaluate candidate genes with respect to their suitability
to serve as blood biomarkers by distinguishing ccRCC
vs. normal patients, their expression was first tested by
RT-qPCR in ccRCC and normal tissues, and secondly in
blood samples of cancer patients versus non-cancer pa-
tients and healthy donors. According to the bioinformat-
ics analysis, the higher expression in ccRCC tissue
would be expected to be confirmed as compared to nor-
mal tissue, and subsequently, when PAXgene blood
samples are tested, the higher expression of at least
some of the candidate genes would hopefully be deter-
mined in PAX blood from cancer patients compared to
healthy. In order to obtain RNA seq based expression
profiles in ccRCC and compare them to normal tissue as
well as blood, the Cancer Genome Atlas database
(TCGA, [31]) was used. The TCGA data portal is the
largest and most commonly used public resource provid-
ing somatic and germline mutation, gene expression,
gene methylation and copy number variation (CNV)
data sets, amongst others, for several thousands of
tumor samples. Data was obtained for 470 ccRCC pa-
tients, including 68 samples from matched normal tis-
sue. In cases where multiple samples corresponded to a
single patient, average expression values were calculated.
Out of 20,533 TCGA genes in total, blood expression
data from sources described below was found for 20,466
genes. Ideally candidate genes should not have wide ex-
pression domains; so as to provide a measure of kidney
specificity for a gene, Tissue-specific Gene Expression
and Regulation database (TiGER, [32]) was consulted,
which is based on the analysis of the NCBI EST database
[33] for 30 human tissues and contains tissue-specific
expression profiles for 20,000 UniGenes. From 458
enriched in kidney, genes also expressed in blood, liver,
prostate and bladder were deducted, leaving a list of 95
conditionally named ‘kidney specific’ genes.
In order to obtain blood expression profiles, a compre-
hensive search for RNA seq expression data from healthy
individuals was made in literature and online databases.
Gene Expression Omnibus database (GEO, [34]) archives
and freely distributes microarray, next-generation sequen-
cing, and other forms of high-throughput functional gen-
omics data. This database was searched by variations of
‘blood [Sample Source] AND Homo sapiens [Organism]
Fig. 1 Workflow diagram
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AND high throughput sequencing [Platform Technology
Type]’ providing a total of seven usable datasets altogether
comprising 91 individual blood samples. Further 376
blood samples were obtained from GTEx database [35]
and an additional source of one blood sample pooled from
five individuals was kindly provided by Dr. Zhao and Dr.
Zhang of Pfizer.
In order for expression profiles in important organs or
organs related to the urological system to be given some
relevance, RNA seq data from normal tissue was also
considered in the analysis. From TCGA database, data
was obtained for normal liver and bladder (9 and 11
samples respectively) and an analogous GEO search re-
sulted in a recovery of a small number of samples for
kidney, liver and bladder. Additional samples for kidney
and liver (pooled from multiple donors) were included
from RNA seq Atlas [36] (Table 1).
Processing of data downloaded from TiGER database,
RNA seq expression data, calculation of rpkm values
(reads per kilobase million) where necessary, translation
of gene names and statistics were done in Python. Rpkm
values were calculated according to the formula: raw
count × 1,000,000/(gene length x library size). Transla-
tion of gene names was done using BioMart [38]. Mann-
Whitey U test was used to discern between cancer and
matched normal samples from TCGA with statistical
significance defined as p < 0.05. In cases of gene expres-
sion entries with multiple isoforms, replicate samples,
duplicate gene names, absolute highest values were
taken, so as not to underestimate the possible presence
in blood.
RNA isolation and RT-qPCR analysis
Total tissue RNA (1 μg) was purified using miRNeasy Kit
(Qiagen, Hilden, Germany) following homogenization
using TissueLyser II (Qiagen). Total RNA from PAXgene
blood tubes was purified using the PAXgene Blood
miRNA Kit (Qiagen). Total RNA concentration was deter-
mined by NanoDrop 1000 Spectrometer (Thermo Fisher
Scientific Inc., Wilmington, DE, USA) by measuring the
absorbance at 260 nm and RNA purity by measuring
A260/280 ratios. The integrity and size distribution of the
tissue and blood derived RNA was analyzed using Bioana-
lyzer (Agilent RNA 6000 Nano Kit). Only samples with
RNA integrity number values equal or above 7 were in-
cluded. RNA samples from normal tissues were pooled
together and the same was done with the ones from
cancer, producing one normal pool (NN) and one cancer
pool (NC). Complementary DNA synthesis was performed
using the Transcriptor First Strand cDNA Synthesis Kit
(Roche Applied Science, Mannheim, Germany) with a mix
of random hexamer and anchored-oligo(dT) primers.
RNA was also isolated and transcribed from the renal
cell carcinoma cell line 786–0 to assess the quality of
all newly made cDNA from tissue and PAXgene blood
samples. Normalization of the RT-qPCR data was done
using the kidney reference gene peptidylproline isomer-
ase A (PPIA) [39].
Primers were designed for SYBR Green using NCBI’s
PrimerBlast and Primer3 (see Additional file 1), so as to
cover the maximum number of isoforms. The criteria
for primer design were: amplicon length 60–150 nt, pri-
mer length 18–30 nt, intron spanning (intron length >
1000 nt), GC content 40–60%. For certain genes UPL
probes were used in which case primers were automatic-
ally suggested with a given probe by the online tool
(Universal Probe Library, Roche [40]), and common as-
says were selected for genes with multiple isoforms.
The relative quantification of transcripts was done on
the Light Cycler 480 (Roche) using the QuantiTec SYBR
Green PCR Kit (Qiagen) as previously described [37]. In
case of UPL probes LightCycler 480 Probes Master Kit
(Roche) was used. PCR was done on 96-well plates, with
kidney cancer cell line 786–0 and ccRCC tissues as posi-
tive controls. PCR conditions were optimized where ne-
cessary and the size of PCR products was confirmed by
electrophoresis using Bioanalyzer (Agilent DNA 1000
Kit). PCR data were analyzed by qBasePLUS software
(Biogazelle NV, Gent, Belgium). With respect to the
qBasePLUS processing, the samples were divided in 2 or
Table 1 Sources of expression profile datasets
Database Tissue Sample
number
Source
GEO/GSE53655 blood 6 whole blood/PAXgene
GEO/GSE72509 blood 18 whole blood/PAXgene
GEO/GSE51799 blood 6 whole blood/PAXgene
GEO/GSE51799 blood 16 peripheral blood
mononuclear cells
GEO/GSM833103 blood 16 whole blood/
PAXgene
GEO/GSM1647922,
Personal
correspondence
blood 12 whole blood/EDTA,
Tempus
Personal
correspondence,
Pfizer [37]
blood 1, pooled
from 5
whole blood/PAXgene
GTEx blood 376 whole blood
TCGA liver,
normal matched
9 cancer patients
TCGA bladder,
normal matched
11 cancer patients
GEO/GSE69360 kidney 2 adult normal tissue
GEO/GSE69360 liver 2 adult normal tissue
RNA seq Atlas kidney 1, pooled normal tissue
RNA seq Atlas liver 1, pooled normal tissue
GEO/GSE35178 bladder 1 adult normal tissue
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3 groups: normal vs. all cancer samples, i.e. cancer and
metastatic cancer in a single group, as shown in the
table ‘qBasePLUS results: normal vs. all cancer samples’
(see Additional file 2), normal vs. non-metastatic cancer,
normal vs. metastatic cancer, and non-metastatic cancer
vs. metastatic, as shown in the table ‘qBasePLUS results:
non-metastatic cancer vs. metastatic samples’ (see Add-
itional file 3). Results were calculated for 100% PCR effi-
ciency and ´unpaired´ experimental design.
Statistics
Statistical analysis was done with GraphPad Prism 6.07
(GraphPad Software, San Diego, CA, USA) and qBase-
PLUS, using the Mann-Whitney U-test. P values < 0.05
were considered statistically significant. Graphs were
generated in GraphPad Prism using the Mann-Whitney
U-test.
Results
Candidate gene selection
In order to obtain a list of genes potentially useful as
biomarkers, only genes with supposedly no blood ex-
pression, favorable statistical distance between distribu-
tions of cancer and normal values and high expression
in cancer were taken into account. Regarding blood ex-
pression, values below 1 rpkm were considered low
enough as to signify possible non expression, with re-
spect to the sensitivity of detection. As a measure of dis-
tance of cancer and matched normal tissue distributions,
the ratio of 5th percentile of cancer distribution with
95th percentile from normal was taken, and values above
0.5 considered favorable. Another measure of distance
was calculated where the score represents the multipli-
cation of probabilities of patients from each distribution
falling within the overlap interval (score = Xprob x
Yprob). Individual probabilities are calculated as the
number of patients whose rpkm values fall within the
overlap interval, divided by the total number of patients
in the distribution (Xprob = patients within the overlap
interval/total number of patients). Score is assigned 0 if
the distributions do not overlap, and 1 for identical dis-
tributions. In cases when one distribution is within the
other, but there are no patients from the larger one
which fall into the overlap interval (they are distributed
on both sides of it) score is assigned 1 as those genes are
not valuable for further analysis. This method of calcu-
lating statistical distance is generally stricter then the
percentile ratio, with favorable distance represented by
values less than 0.3.
For genes of interest, the expression levels in liver,
bladder, prostate and kidney in healthy individuals were
also taken into account, giving preferential ranking to
genes with lower rpkm values. Literature, the Human
Protein Atlas [41], and OMIM [42] were consulted to
gather information regarding gene function and expres-
sion domains of selected genes. Gene functions related
to metabolic pathways in kidney or implicated in cancer
(especially genes linked to ccRCC and hypoxia-inducible
factors HIF1α and HIF2α) together with absence of ex-
pression in bone marrow and immune system, low or no
expression in most tissues, and enrichment in kidney
were considered favorable with respect to gene ranking.
A group of 20 genes were found to strictly fulfill ex-
pression criteria (defined as: blood expression GEO
sources 95th percentile <1rpkm, GTEx 95th percentile
<=1; fold change TCGA cancer median/matched normal
tissue median > 1; distribution distance 5th percentile
TCGA cancer/95th percentile matched normal tissue >
0.5, TCGA cancer median > 5rpkm) (Table 2, first 20
genes). The first 13 genes have median cancer values
above 10. In addition, when it is considered that the rate
of release of RNA from ccRCC into blood may be much
higher than from normal kidney, as well as the presence
of circulating tumor cells, the fold change median can-
cer/matched normal tissue, as well as the percentile ratio
distribution distance measure become less relevant and
may be relaxed in terms of gene selection. A similar ar-
gument follows for blood expression considering that in-
dividual blood sources may not be fully reliable and false
outliers may be present. This enables the inclusion of
certain genes which do not satisfy all the criteria fully,
but may excel in some (last 11 genes in the table).
Many of these genes have previously been implicated
in ccRCC, largely in micro-array studies [43–50]. This
analysis identified this group of genes as having zero or
low RNA blood presence, suggesting their potential use
as ccRCC biomarkers in blood.
Analysis of the expression of candidate genes
To obtain an approximate overview of the levels in tis-
sue, the expression was analyzed in cancer versus nor-
mal tissue for 15 genes of highest interest and the
bioinformatics analysis was confirmed, as all these genes
showed increased levels in cancer, notably so CA9 and
NDUFA4L2 (Fig. 2). Certain genes were excluded from
the analysis because of detection issues (multiple iso-
forms, etc.).
Blood testing consisted of two stages: in the first stage
3 PAXgene cancer samples were used (Table 3), and
only genes with good (Cq < 33) detectability were se-
lected for the second stage of blood testing with 24 more
PAXgene samples (13 cancer and 11 normal/healthy), in
order to broadly evaluate their expression. Especially
good detectability was shown for following genes:
CDK18 (Cq = 27), EGLN3 (Cq = 26), TMEM45A (Cq =
28), CAV2 (Cq = 26). A larger number of genes was un-
detectable or with extremely high Cq values. The genes
with the supposedly highest potential based on
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bioinformatics and tissue PCR analysis (NDUFA4L2 and
CA9) had low detectability with very high Cq values
(around 34). Nevertheless, NDUFA4L2 was tested on all
27 samples and was confirmed to be undetectable. In
summary, 9 genes were finally selected for the second
stage of testing (CAV2a, FABP7, ESM1, NOL3, LOX,
CDK18, EGLN3, TMEM45A, CCND1). In the second
stage, the expression levels turned out to be similar in
cancer versus normal blood for most genes, except for
CDK18 and CCND1 which paradoxically turned out to be
downregulated in cancer blood (Table 4). Additional test-
ing with 10 plasma samples indicated non-measurable
expression. There was no correlation between the expres-
sion levels in blood for CDK18, CCND1, and LOX, and
patient data such as age, tumor grade and stage.
The downregulation of CDK18 RNA in cancer blood
(metastatic and non-metastatic grouped together) com-
pared to normal was significant with p value = 0.001,
Table 2 Candidate genes
GENE MEDIAN RPKM in
ccRCC (based on
expression data from
TCGA consortium,
[31])
FOLD DIFFERENCE,
median rpkm in
ccRCC vs. median
rpkm in normal
kidney (based on
expression data
from TCGA
consortium, [31])
RPKM DISTRIBUTION
DISTANCE,
5th percentile ccRCC/
95th percentile normal
kidney (based on
expression data from
TCGA consortium, [31])
BLOOD RPKM value
of 95th percentile
(based on GEO
database [34])
BLOOD RPKM value
of 95th percentile
(based on GTEx
database [35])
NDUFA4L2 701 145 1.06 0.16 0.15
EGLN3 174 23.2 0.93 0.72 0.62
CA9 117 1218 3.74 1 0.13
CCND1 138 4.34 0.58 0.58 0.37
CAV2 110 3.98 0.69 0.43 0.43
ESM1 92.5 12.4 0.6 0.77 0.2
PPP1R3C 20.1 3.66 0.54 0.03 0.67
STC2 19.1 22.3 1.33 0 0.07
NPTX2 18.4 150 1.48 0.07 0.13
ANGPT2 17.1 10.4 0.54 0.11 0.08
DGCR5 15.2 25.9 0.99 0.3 0.17
DOCK6 13.2 2.08 0.51 0.26 0.68
FABP6 11.9 91.3 1.18 0.62 0.85
TMEM133 8.9 2.67 0.52 0.60 0.24
LZTS1 8.81 5.54 0.52 0.26 0.25
COX4I2 6.85 4.37 0.52 0.06 0.15
KIAA1274 6.71 4.11 0.58 0.78 0.41
LPIN3 6.14 2.29 0.54 0.12 0.17
FKBP9L 6.11 1.32 0.51 0.71 0.14
RAB42 5.90 5.47 1.02 0.17 0.49
MET 112 2.08 0.36 0.07 0.1
CDK18 85.4 5.29 0.28 1.21 0.85
CP 79.7 21.3 0.11 0.89 0.4
TMEM45A 62.9 2.43 0.71 0.13 2.31
LOX 51.0 10.8 0.22 0.22 0.29
GAL3ST1 49.4 8.14 0.3 0.15 0.11
CYP2J2 49 39.3 0.27 0.65 0.2
NOL3 44.1 10.6 1.36 1.98 2.47
FBXO17 38.7 2.77 0.5 2 0.12
FABP7 19.9 974 0.22 0 0.05
BARX2 19.1 6.01 0.27 0.42 0.04
Simonovic et al. BMC Urology            (2020) 20:7 Page 6 of 12
whereas CCND1 was downregulated with p = 0.039
(Fig. 3). For both genes, there was no significant differ-
ence in levels when non-metastatic and metastatic sam-
ples were compared with each other. The results also
showed a tendency towards upregulation for LOX when
non-metastatic were compared to metastatic cancer
samples, with the p value very close to significant (p =
0.058) (Fig. 3).
Discussion
In this study, a gene panel was made comprising the
most highly overexpressed genes in ccRCC tissue whose
mRNA also had the potential of being absent in the
blood of healthy individuals. The first stage in the con-
struction of this panel was the TCGA database- to select
a panel of the most overexpressed genes in ccRCC,
followed by the GEO and GTEx databases- to deduct
from this panel genes showing measurable expression in
the blood of healthy individuals. After confirming the
tissue overexpression on samples from ccRCC patients
in the next step, RT-qPCR analysis was done to evaluate
mRNA levels in whole blood of ccRCC patients vs. pa-
tients without ccRCC and healthy donors. Measurable
genes did not show overexpression in normal blood
while two genes exhibited downregulation.
Whole blood analysis of selected genes does not show
increased mRNA levels
The genes that had highest potential based on the bio-
informatics analysis were NDUFA4L2 and CA9. Accord-
ing to the TCGA, the former has very high median
expression in ccRCC tissue (701 rpkm) whereas the lat-
ter has the highest overexpression in ccRCC compared
to normal tissue (1218). However, we found both to be
undetectable in whole blood by qPCR. Several other
Fig. 2 Confirmation of TCGA data by RT-qPCR: Candidate genes
were overexpressed in ccRcc compared to normal tissue (all values
are above 1). Fold change is calculated as 2exp (Cqnormal-Cqcancer)
Table 3 Evaluation of candidate genes by RT-qPCR in tissue
and 3 blood samples
Candidate genes Confirmed Higher
Expression In Ccrcc
Vs Normal Tissue;
fold change cancer/
normal
Detectability In 3
PAX blood ccRCC
SAMPLES, mean
Cq value
NDUFA4L2 yes; 133 > 33
EGLN3 yes; 25 26.1
CA9 yes; 1938 > 33
CCND1 yes; 5 31.5
CAV2 not tested 26.1
ESM1 not tested 30.6
PPP1R3C yes; 5 > 33
STC2 yes; 3 > 33
NPTX2 yes; 24 > 33
ANGPT2 yes; 24 > 33
DOCK6 yes; 1 > 33
FABP6 not tested > 33
MET not tested > 33
CDK18 yes; 2 27.6
CP yes; 40 > 33
TMEM45A yes; 9 28.8
LOX not tested 30.7
GAL3ST1 not tested > 33
CYP2J2 yes; 19 > 33
NOL3 not tested 29.8
FABP7 not tested 32.5
BARX2 yes; 9 > 33
Table 4 Evaluation of expression in the second stage of blood
testing with 27 samples
Candidate genes Fold change
cancer/normal
P value Significantly different
expression of ccRCC vs.
normal in 27 pax blood
samples
EGLN3 −1.26 0.215 No
CCND1 −1.55 0.039 Downregulated in ccRCC
CAV2 1.16 0.497 No
ESM1 −1.21 0.668 No
CDK18 −2.10 0.001 Downregulated in ccRCC
TMEM45A −1.04 0.734 No
LOX −1.31 0.668 No, tendency towards
upregulation in
metastatic ccRCC
NOL3 −1.05 0.641 No
FABP7 −1.13 0.671 No
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Fig. 3 Blood relative mRNA expression of CDK18, CCND1, and LOX based on the qBase exported relative quantity (RQ) values, calculated from Cq
values, according to the formula: RQ = 2 (meanCq-Cq); results from qBase (RQ values) were processed in GraphPad Prism in order to generate graphs
using the Mann-Whitney U-test. N- normal patient samples; T- tumor patient samples; mT- metastatic. a CDK18 was underexpressed in PAX blood
tumor samples compared to normal PAX blood. b There is no significant difference in expression of CDK18 between tumor and metastatic tumor
PAX blood samples. c CCND1 was underexpressed in PAX blood tumor samples compared to normal PAX blood. d There is no significant
difference in expression of CCND1 between tumor and metastatic tumor PAX blood samples. e There is no significant difference in expression of
LOX in PAX blood tumor samples compared to normal PAX blood. f Lox shows a tendency towards upregulation in metastatic compared to
non-metastatic tumor PAX blood samples
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candidate genes were found to be undetectable in whole
blood, while most of the genes that were detectable
(EGLN3, CAV2, ESM1, TMEM45A, NOL3, FABP7) did
not exhibit significant dysregulation in expression be-
tween cancer and healthy PAXgene samples. A plausible
path to overcoming this outcome was to examine these
genes in plasma, as the mRNA levels (supposedly origin-
ating from the expression in blood cells) could signifi-
cantly drop in healthy samples compared to cancer ones
once the blood cells are removed, revealing the effect of
the tumor derived RNA. However, after testing 10
plasma samples, our conclusion was that gene expres-
sion in the plasma was not measurable. The PAXgene
system is used for stabilization and isolation of mRNA
and other classes of nucleic acids (such as genomic
DNA and miRNA). Blood specimens are collected in
tubes containing a stabilization reagent preventing nu-
clease degradation and transcriptional changes in antic-
oagulated whole blood, and stabilizing RNA for up to 3
days at room temperature, for the purpose of expression
profiling [51]. All handling of RNA was done with spe-
cial care, and although it is reasonable to assume that
for many or all of the candidate genes RNA was de-
graded by blood RNAses, the RNA integrity of whole
PAXgene samples was indeed satisfactory, reflected by
their high RIN values. Apart from the issues regarding
RNA stability and concerning expression interference
from blood cells, possible limitations of this work design
may stem from the bioinformatics phase. Acquired GEO
datasets, which were used to screen for genes absent
from blood (with supposedly no blood expression) may
not be 100% reliable; they came from many different
sources and were not in a perfect mutual accordance. A
separate issue is the cutoff value of < 1 rpkm to signify
absence of blood presence for a gene. Most authors
somewhat arbitrarily define the expression threshold as
1 rpkm (more generally anywhere between 0.3 rpkm and
1 rpkm), below which the sensitivity of RNA sequencing
is insufficient to confirm expression and distinguish it
from the background [52, 53]. Our cutoff potentially
may have enabled genes with minute expression in blood
cells to be included in the wet lab analysis.
CDK18, CCND1, lox
The study also revealed the downregulation of two genes,
CDK18 and CCND1, in ccRCC blood compared to
healthy samples, as well as a tendency towards upregula-
tion for LOX in metastatic compared to non-metastatic
ccRCC. These results may be suitable for additional ana-
lysis in a larger patient cohort.
Cyclin-dependent kinase 18 (CDK18, PCTK3,
PCTAIRE, PCTAIRE3) belongs to the PCTAIRE protein
kinases, which are a subfamily of cdc2-related serine/
threonine protein kinases named for a cysteine-for-
serine substitution in the PCTAIRE motif conserved in
the initially characterized CDK proteins (PCTAIRE se-
quence instead of the PSTAIRE sequence). They have
unique N and C-terminal domains that extend forth
from a serine/threonine kinase domain that is highly
homologous to cdc2 [54]. PCTAIRE kinase subfamily in-
cludes three members, PCTK1/CDK16, PCTK2/CDK17,
and PCTK3/CDK18 which are poorly researched. In-
sights into the activation of CDK18 have recently been
obtained- it binds cyclin A2 and cyclin E1 (pulldown ex-
periment with HEK293T cells) and is activated by cyclin
A2 and PKA (cAMP-dependent protein kinase) [55].
CDK18 has recently been shown to regulate cell migra-
tion and adhesion in HEK293T cells by negatively
modulating FAK (focal adhesion kinase) activity and re-
organizing actin and associated skeletal/adhesion pro-
teins such as cofilin, and has also been implicated in
vesicular transport via interaction with Sec23Ap [56].
Overexpression of CDK18 also led to the formation of
filopodia during the early stages of cell adhesion in HeLa
cells [57]. Interestingly, it has also been recently found
to play a role in replication stress and positively regulate
genome stability, by associating with RAD proteins [58].
Lastly, PCTAIRE-3 as well as PCTAIRE-2 have been
implicated in Alzheimer’s disease [59, 60]. CDK18 was
induced by CTS-1 (Chimeric tumor suppressor-1, p53-
derived synthetic tumor suppressor) and mediated
growth arrest and death in glioma cells [61]. Apart from
its activation by cyclin A2, in the same study CDK18
was shown to phosphorylate retinoblastoma tumorsu-
pressor protein (Rb) in vitro [55]. Although PCTAIRE1
has been found to be upregulated in many cancers, so far
there is no such data for CDK18.
Cyclin D1 (CCND1) regulates CDK4 or CDK6, whose
activity is necessary for G1/S transition of the cell cycle.
CCND1 is more frequently dysregulated in human can-
cers and therefore more studied than cyclin D2 or D3.
Its overexpression leads to aberrant CDK activation
resulting in rapid growth and division and is correlated
with tumor stage, increased metastasis and poor progno-
sis in various cancers [62]. It is also involved in
processes such as DNA repair and the control of mito-
chondrial activity and cell migration; it may assume
CDK-independent functions as well [63]. CCND1 was
investigated by microarray and TMA in ccRCC, and
found to be upregulated and a potential therapeutic tar-
get [64]. In another study, CCND1 was found to be a
useful immunohistochemical marker to discriminate be-
tween chromophobe renal cell carcinoma and renal
oncocytoma [65].
Lysyl oxidase (LOX) performs covalent cross linking in
elastin and collagen by oxidizing lysine residues, and
therefore is important for the integrity of extracellular
matrix [66]. It has both intracellular and extracellular
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functions and is involved in a number of pathological
processes that affect the connective tissue [67]. It is up-
regulated in many cancers and involved in tumor pro-
gression, although it has been reported to function as a
tumor-suppressor as well. Its concrete roles in various
aspects of tumorigenesis have been reviewed recently
[68]. LOX is a HIF target [69] and in ccRCC, LOX has
been shown to be strongly overexpressed compared to
normal tissue; it is one of the genes postranscriptionally
regulated by miR-141-3p and miR-145-5p; and has prog-
nostic relevance for the overall survival of ccRCC pa-
tients [70]. In ccRCC cell cultures, it has been found to
function in a positive-regulative loop with HIF-1α, and
to influence ccRCC progression by modifying cellular
adhesion, migration, and the rigidity of the collagen
matrix [71].
Conclusions
In summary, with the goal of finding potential blood-
based biomarkers for ccRCC, this study investigated the
blood presence of genes highly overexpressed in ccRCC
tissue and compared their blood mRNA levels between
healthy and ccRCC patient samples. The overexpression
in tissue was not reflected in the increase in the levels of
mRNAs circulating in the blood of ccRCC patients. The
analysis revealed the transcripts of CDK18 and CCND1
as underexpressed in the blood of ccRCC patients, and
LOX as showing a tendency towards upregulation in
metastatic ccRCC compared to non-metastatic. Further
analysis of the selected gene panel by using a larger pa-
tient cohort may prove useful.
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